50 related articles for article (PubMed ID: 30277862)
1. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
[TBL] [Abstract][Full Text] [Related]
2. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.
Ilowite NT; Prather K; Lokhnygina Y; Schanberg LE; Elder M; Milojevic D; Verbsky JW; Spalding SJ; Kimura Y; Imundo LF; Punaro MG; Sherry DD; Tarvin SE; Zemel LS; Birmingham JD; Gottlieb BS; Miller ML; O'Neil K; Ruth NM; Wallace CA; Singer NG; Sandborg CI
Arthritis Rheumatol; 2014 Sep; 66(9):2570-9. PubMed ID: 24839206
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
[TBL] [Abstract][Full Text] [Related]
5. Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.
Haddon DJ; Wand HE; Jarrell JA; Spiera RF; Utz PJ; Gordon JK; Chung LS
J Rheumatol; 2017 May; 44(5):631-638. PubMed ID: 28298564
[TBL] [Abstract][Full Text] [Related]
6. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
Khanna D; Huang S; Lin CJF; Spino C
Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
[TBL] [Abstract][Full Text] [Related]
7. Testing a candidate composite serum protein marker of skin severity in systemic sclerosis.
Roblin E; Clark KEN; Beesley C; Ong VH; Denton CP
Rheumatol Adv Pract; 2024; 8(2):rkae039. PubMed ID: 38645474
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.
Neve M; Diderichsen PM; Helmer E; de Vries D; Taneja A
ACR Open Rheumatol; 2024 Jun; ():. PubMed ID: 38923416
[TBL] [Abstract][Full Text] [Related]
9. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
Imazio M; Klein AL; Brucato A; Abbate A; Arad M; Cremer PC; Insalaco A; LeWinter MM; Lewis BS; Lin D; Luis SA; Nicholls SJ; Sutej P; Wasserstrum Y; Clair J; Agarwal I; Wang S; Paolini JF;
J Am Heart Assoc; 2024 Mar; 13(6):e032516. PubMed ID: 38471825
[TBL] [Abstract][Full Text] [Related]
10. Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease.
Woo S; Gandhi S; Ghincea A; Saber T; Lee CJ; Ryu C
Front Cell Dev Biol; 2023; 11():1254904. PubMed ID: 37849737
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis.
Solomonidi N; Vlachoyiannopoulos PG; Pappa M; Liantinioti G; Ktena S; Theotikos E; Elezoglou A; Netea MG; Giamarellos-Bourboulis EJ
iScience; 2023 Sep; 26(9):107670. PubMed ID: 37680472
[TBL] [Abstract][Full Text] [Related]
12. Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies.
Ferlito A; Campochiaro C; Tomelleri A; Dagna L; De Luca G
J Scleroderma Relat Disord; 2022 Oct; 7(3):179-188. PubMed ID: 36211207
[TBL] [Abstract][Full Text] [Related]
13. Assessment of disease outcome measures in systemic sclerosis.
Lafyatis R; Valenzi E
Nat Rev Rheumatol; 2022 Sep; 18(9):527-541. PubMed ID: 35859133
[TBL] [Abstract][Full Text] [Related]
14. Autologous Skin Fibroblast-Based PLGA Nanoparticles for Treating Multiorgan Fibrosis.
Long Q; Liu Z; Shao Q; Shi H; Huang S; Jiang C; Qian B; Zhong Y; He X; Xiang X; Yang Y; Li B; Yan X; Zhao Q; Wei X; Santos HA; Ye X
Adv Sci (Weinh); 2022 Jul; 9(21):e2200856. PubMed ID: 35603964
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.
Papadimitriou TI; van Caam A; van der Kraan PM; Thurlings RM
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203525
[TBL] [Abstract][Full Text] [Related]
16. Myofibroblast transcriptome indicates SFRP2
Tabib T; Huang M; Morse N; Papazoglou A; Behera R; Jia M; Bulik M; Monier DE; Benos PV; Chen W; Domsic R; Lafyatis R
Nat Commun; 2021 Jul; 12(1):4384. PubMed ID: 34282151
[TBL] [Abstract][Full Text] [Related]
17. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.
Wolff D; Radojcic V; Lafyatis R; Cinar R; Rosenstein RK; Cowen EW; Cheng GS; Sheshadri A; Bergeron A; Williams KM; Todd JL; Teshima T; Cuvelier GDE; Holler E; McCurdy SR; Jenq RR; Hanash AM; Jacobsohn D; Santomasso BD; Jain S; Ogawa Y; Steven P; Luo ZK; Dietrich-Ntoukas T; Saban D; Bilic E; Penack O; Griffith LM; Cowden M; Martin PJ; Greinix HT; Sarantopoulos S; Socie G; Blazar BR; Pidala J; Kitko CL; Couriel DR; Cutler C; Schultz KR; Pavletic SZ; Lee SJ; Paczesny S
Transplant Cell Ther; 2021 Oct; 27(10):817-835. PubMed ID: 34217703
[TBL] [Abstract][Full Text] [Related]
18. New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy.
Romano E; Rosa I; Fioretto BS; Matucci-Cerinic M; Manetti M
Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34202703
[TBL] [Abstract][Full Text] [Related]
19. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
Campochiaro C; Allanore Y
Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis (scleroderma): remaining challenges.
Connolly MK
Ann Transl Med; 2021 Mar; 9(5):438. PubMed ID: 33842659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
